ACA
REGN icon

Anchor Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Anchor Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Sell
1,880
-8,418
-82% -$5.73M 0.03% 163
2026
Q1 		$7.96M Sell
10,298
-2,201
-18% -$1.69M 0.23% 91
2025
Q4 		$9.65M Buy
12,499
+702
+6% +$477K 0.28% 92
2025
Q3 		$6.63M Buy
11,797
+425
+4% +$240K 0.19% 100
2025
Q2 		$5.97M Buy
11,372
+375
+3% +$209K 0.18% 106
2025
Q1 		$6.97M Buy
10,997
+150
+1% +$103K 0.21% 103
2024
Q4 		$7.73M Buy
+10,847
New +$9.1M 0.22% 107

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Anchor Capital Advisors's REGN Position: Q2 2026 in Review

Anchor Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 82% in Q2 2026, selling an estimated $5.73M and leaving 1,880 shares worth $1.17M. The position accounts for 0.03% of the portfolio, ranked #163.

Anchor Capital Advisors first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.65M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Anchor Capital Advisors held 1,880 shares of Regeneron Pharmaceuticals worth $1.17M as of Q2 2026.
  • Anchor Capital Advisors sold 8,418 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.73M.
  • Regeneron Pharmaceuticals made up 0.03% of Anchor Capital Advisors's portfolio in Q2 2026, its #163 holding.
  • Anchor Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Anchor Capital Advisors's Regeneron Pharmaceuticals position peaked at $9.65M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Anchor Capital Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.